Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

MLA

De Novellis, Danilo, et al. “Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.” European Journal of Haematology, Oct. 2024. EBSCOhost, https://doi.org/10.1111/ejh.14314.

APA

De Novellis, D., Derudas, D., Vincelli, D., Fontana, R., Della Pepa, R., Palmieri, S., Accardi, F., Rotondo, F., Morelli, E., Gigliotta, E., Roccotelli, D., Marano, L., Barone, M. L., Cetani, G., Esposito, D., Lazzaro, A., Delle Cave, G., Serio, B., Morini, D., … Selleri, C. (2024). Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. European Journal of Haematology. https://doi.org/10.1111/ejh.14314

Chicago

De Novellis, Danilo, Daniele Derudas, Donatella Vincelli, Raffaele Fontana, Roberta Della Pepa, Salvatore Palmieri, Fabrizio Accardi, et al. 2024. “Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.” European Journal of Haematology, October. doi:10.1111/ejh.14314.